Table 3.
Factors associated with AEs following mass triple therapy in comparison to dual therapy
| Variables | Triple therapy (IDA) | Dual therapy (DA) | ||
|---|---|---|---|---|
| Incidence of AEs, n (%) | p-value | Incidence of AEs, n (%) | p-value | |
| Sex | ||||
| Female | 1511/5369 (28.1%) | 0.04 | 881/5343 (16.5%) | 0.39 |
| Male | 1328/5042 (26.3%) | 740/4667 (15.9%) | ||
| Age, years | ||||
| 2–15 | 742/3224 (23.0%) | < 0.001 | 661/4456 (14.8%) | < 0.001 |
| 16–20 | 330/1173 (28.1%) | 259/1315 (19.7%) | ||
| 21–64 | 1732/5892 (29.4%) | 638/3949 (16.2%) | ||
| 65–99 | 35/122 (28.7%) | 63/290 (21.7%) | ||
| Took concomitant medication | ||||
| Yes | 175/608 (28.8%) | 0.39 | 113/436 (25.9%) | < 0.001 |
| No | 2664/9803 (27.2%) | 1508/9574 (15.8%) | ||
| Number of DEC tablets taken | ||||
| 1 | 240/1260 (19.0%) | < 0.001 | 233/1721 (13.5%) | < 0.001 |
| 2 | 304/1328 (22.9%) | 357/2383 (15.0%) | ||
| 3 | 1204/4202 (28.7%) | 1026/5880 (17.4%) | ||
| 4 | 1088/3606 (30.2%) | 5/26 (19.2%) | ||
| Ivermectin tablets | ||||
| 1 | 242/1232 (19.6%) | < 0.001 | ||
| 2 | 300/1317 (22.8%) | |||
| 3 | 1209/4220 (28.6%) | |||
| 4 | 1088/3642 (29.9%) | |||
| Chronic illness | ||||
| Yes | 86/264 (32.6%) | 0.05 | 20/82 (24.4%) | 0.04 |
| No | 2753/10147 (27.1%) | 1601/9928 (16.1%) | ||
| Type of meal | ||||
| Carbohydrate | 1635/6598 (24.8%) | < 0.001 | 735/5171 (14.2%) | < 0.001 |
| High fat | 363/1266 (28.7%) | 160/911 (17.6%) | ||
| High protein | 375/1080 (34.7%) | 150/754 (19.9%) | ||
| Pre-MDA clinical events | ||||
| Yes | 281/909 (30.9%) | 0.01 | 67/352 (19.0%) | 0.14 |
| No | 2558/9502 (26.9%) | 1554/9658 (16.1%) | ||
AEs adverse events, DA diethylcarbamnzine + albendazole, DEC diethylcarbamazine citrate, IDA ivermectin + diethylcarbazine + albendazole, MDA mass drug administration